News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
395,264 Results
Type
Article (31841)
Company Profile (58)
Press Release (363365)
Section
Business (112722)
Career Advice (1321)
Deals (24041)
Drug Delivery (92)
Drug Development (59669)
Employer Resources (102)
FDA (9923)
Job Trends (9075)
News (211370)
Policy (25490)
Tag
2024 BioCapital Digital (1)
2024 BioMidwest Digital (1)
2024 Bio NC Digital (1)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (4)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (1)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (1)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (1)
2026 BioCapital Standard (1)
2026 Pharm Country Premier (1)
Academia (1834)
Accelerated approval (1)
Adcomms (20)
Allergies (61)
Alliances (42225)
ALS (52)
Alzheimer's disease (1070)
Antibody-drug conjugate (ADC) (81)
Approvals (9908)
Artificial intelligence (137)
Autoimmune disease (10)
Automation (6)
Bankruptcy (232)
Best Places to Work (7694)
BIOSECURE Act (15)
Biosimilars (71)
Biotechnology (42)
Bladder cancer (41)
Brain cancer (25)
Breast cancer (164)
Cancer (1344)
Cardiovascular disease (99)
Career advice (1108)
Career pathing (19)
CAR-T (93)
Cell therapy (266)
Cervical cancer (12)
Clinical research (47888)
Collaboration (593)
Compensation (338)
Complete response letters (18)
COVID-19 (2464)
CRISPR (25)
C-suite (90)
Cystic fibrosis (56)
Data (1264)
Decentralized trials (1)
Denatured (9)
Depression (32)
Diabetes (187)
Diagnostics (3530)
Digital health (10)
Diversity (4)
Diversity, equity & inclusion (33)
Drug discovery (76)
Drug pricing (94)
Drug shortages (28)
Duchenne muscular dystrophy (59)
Earnings (39948)
Editorial (29)
Employer branding (13)
Employer resources (93)
Events (45375)
Executive appointments (269)
FDA (10616)
Featured Employer (18)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (407)
Gene editing (63)
Generative AI (12)
Gene therapy (201)
GLP-1 (650)
Government (4059)
Grass and pollen (3)
Guidances (33)
Healthcare (11407)
Huntington's disease (18)
IgA nephropathy (17)
Immunology and inflammation (64)
Indications (19)
Infectious disease (2582)
Inflammatory bowel disease (74)
Inflation Reduction Act (7)
Influenza (43)
Intellectual property (56)
Interviews (230)
IPO (10425)
IRA (40)
Job creations (1747)
Job search strategy (956)
Kidney cancer (7)
Labor market (11)
Layoffs (268)
Leadership (7)
Legal (7041)
Liver cancer (49)
Lung cancer (194)
Lymphoma (93)
Machine learning (2)
Management (31)
Manufacturing (189)
MASH (45)
Medical device (5899)
Medtech (5900)
Mergers & acquisitions (13932)
Metabolic disorders (516)
Multiple sclerosis (44)
NASH (20)
Neurodegenerative disease (58)
Neuropsychiatric disorders (21)
Neuroscience (1404)
NextGen: Class of 2025 (3656)
Non-profit (2769)
Northern California (1399)
Now hiring (4)
Obesity (298)
Opinion (187)
Ovarian cancer (43)
Pain (42)
Pancreatic cancer (58)
Parkinson's disease (96)
Partnered (9)
Patents (131)
Patient recruitment (47)
Peanut (37)
People (24709)
Pharmaceutical (18)
Pharmacy benefit managers (10)
Phase I (14468)
Phase II (20808)
Phase III (16865)
Pipeline (631)
Podcasts (34)
Policy (95)
Postmarket research (1846)
Preclinical (5967)
Press Release (28)
Prostate cancer (67)
Psychedelics (28)
Radiopharmaceuticals (201)
Rare diseases (242)
Real estate (2576)
Recruiting (43)
Regulatory (15972)
Reports (20)
Research institute (1590)
Resumes & cover letters (195)
Rett syndrome (2)
RNA editing (2)
RSV (41)
Schizophrenia (57)
Series A (68)
Series B (34)
Service/supplier (4)
Sickle cell disease (37)
Southern California (1141)
Special edition (4)
Sponsored (18)
Startups (1883)
State (1)
Stomach cancer (11)
Supply chain (45)
The Weekly (25)
United States (11488)
Vaccines (659)
Venture capitalists (22)
Webinars (5)
Weight loss (232)
Women's health (13)
Worklife (8)
Date
Today (58)
Last 7 days (435)
Last 30 days (1717)
Last 365 days (21733)
2025 (3801)
2024 (22352)
2023 (25258)
2022 (33379)
2021 (35888)
2020 (34071)
2019 (27908)
2018 (21234)
2017 (20187)
2016 (18692)
2015 (21494)
2014 (15948)
2013 (12876)
2012 (13623)
2011 (14401)
2010 (13078)
Location
Africa (569)
Alabama (29)
Alaska (3)
Arizona (81)
Arkansas (5)
Asia (25767)
Australia (4653)
California (3050)
Canada (1085)
China (293)
Colorado (133)
Connecticut (141)
Delaware (82)
Europe (61778)
Florida (458)
Georgia (107)
Hawaii (1)
Idaho (28)
Illinois (256)
India (19)
Indiana (172)
Iowa (4)
Japan (99)
Kansas (58)
Kentucky (15)
Louisiana (7)
Maine (27)
Maryland (582)
Massachusetts (2210)
Michigan (97)
Minnesota (121)
Mississippi (1)
Missouri (44)
Montana (20)
Nebraska (10)
Nevada (34)
New Hampshire (19)
New Jersey (959)
New Mexico (14)
New York (929)
North Carolina (456)
North Dakota (4)
Northern California (1399)
Ohio (101)
Oklahoma (6)
Oregon (10)
Pennsylvania (676)
Puerto Rico (3)
Rhode Island (11)
South America (794)
South Carolina (7)
South Dakota (1)
Southern California (1141)
Tennessee (45)
Texas (385)
Utah (72)
Virginia (76)
Washington D.C. (33)
Washington State (269)
West Virginia (2)
Wisconsin (23)
395,264 Results for "bioversys ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million
BioVersys AG announced the expansion of its strategic collaboration with the global biopharma company GSK plc to accelerate the clinical development of alpibectir for the treatment of tuberculosis.
May 7, 2024
·
4 min read
BioVersys Awarded Non-Dilutive Funding From CF AMR Syndicate Collaborative Discovery Programme
BioVersys AG announced that it has received a non-dilutive award from the CF AMR Syndicate of up to £ 500,000, via a LifeArc funded Collaborative Discovery Programme award, to support the development of novel small molecules targeting difficult to treat non-tubercular mycobacteria lung disease in people with cystic fibrosis.
June 4, 2024
·
10 min read
Press Releases
BioVersys Joins EU-Funded RespiriNTM Programme to Accelerate Development of Its Broad-Spectrum Drug Candidates Against NTM Pulmonary Diseases
October 22, 2024
·
8 min read
Press Releases
Bioversys Announces Strategic Investment From GIBF2 and Launch of BV100 Clinical Program in China
September 11, 2024
·
4 min read
Press Releases
Bioversys Announces Last Patient Last Visit in BV100 Phase 2 Clinical Trial in Ventilator Associated Bacterial Pneumonia (VABP) and Provides a Business Update
October 16, 2024
·
9 min read
Deals
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.
June 20, 2024
·
4 min read
Business
OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support
OpGen, Inc. and BioVersys AG today announced the signing of a collaboration agreement for the deployment and use of the Unyvero platform in BioVersys’ upcoming Phase II clinical trial of novel drug candidate BV100.
October 25, 2022
·
6 min read
Vaccines
CDC Panel Recommends Merck and Pfizer Pneumococcal Vaccines for Adults Aged 50–64
The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.
October 24, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products
March 4, 2025
·
5 min read
Press Releases
Medigene AG announces closing of its first SEPA tranche
February 4, 2025
·
2 min read
1 of 39,527
Next
